P&K International is a premier international biochemical company specializing in connecting world-class manufacturers with markets and customers across the globe. Founded in 2026 and headquartered in Singapore, we aimed to connect our branches around the world together.
Our core mission is to bridge the gap between production and consumption, ensuring that our clients receive the high-quality products they need, when they need them, and at competitive price. We act not just as a supplier, but as a strategic resolution provider.
Own 8 FDA approved factories worldwide, with over 14 years of expertise in biochemical trade. Join the 5000+ clients who trust us as their reliable partner in the industry.
Cutting-edge R&D drives your competitive advantage, supported by global reach with deep local expertise across 8 countries. We provide end-to-end solutions, covering everything from raw materials to finished formulation for your diverse needs.
We maintain uncompromising dedication to quality and safety, fully compliant with international standards. Our ESG initiatives are core to our business, and we prioritize building long-term partnerships rooted in mutual success.
In 2012, the branch company Pioneer Biotech was founded in Xi'an and became the general agent of oyster peptide products in China.
In 2013, it operated more than 200 kinds of commonly used raw materials and gradually had its own complete supply chain and market.
In 2015, it was relocated from Lianhu District, Xi'an to Weiyang District, the office hardware was gradually upgraded, and the core team was formed.
In 2016, the first independently developed product, plant-based chitosan, was successfully launched and won a strong response from Shanghai CPHi.
In 2018, the Hanzhong Liaoyang Factory invested by the company was put into use, with shipments of more than 5,000 tons that year.
In 2019, I participated in Vitafoods, SSW, expanded customer acquisition channels, and achieved an annual revenue of 200 million yuan.
In 2020, it controlled the pricing power of HIP in India, authorized sole agency overseas for the first time, acquired an Indian extract factory, and put into use the Tongchuan solid beverage factory.
In 2021, the high-tech research and development center was put into use, and the annual increase in process output value exceeded 35% for the first time, and was rated as a national high-tech enterprise.
In 2022, the U.S. trademark 'QuiPonin' was authorized by the United States and Canada, and the recognition of the company's products in North America was further increased. In the same year, it reached strategic industrial-academia-research cooperation with Shaanxi University of Science and Technology, Xi'an Jiaotong University, Tokyo University, etc. It deeply participated in key industrial chain projects in Shaanxi Province.
In 2023, it was rated as a special new enterprise in Shaanxi Province and a gazelle enterprise; the proportion of revenue and export exceeded 50% for the first time; the pilot workshop of Fengze Industrial Park was rebuilt.
In 2024, it was rated as the 'Manufacturing Single Champion', an enterprise above the scale; the company launched the Colorado factory project in the United States
In 2025, start the construction of Singapore headquarters; build overseas warehouses in global key markets;
